1
|
Redwanz C, Pires RH, Biedenweg D, Groß S, Otto O, Könemann S. Endothelin-1 influences mechanical properties and contractility of hiPSC derived cardiomyocytes resulting in diastolic dysfunction. J Mol Cell Cardiol 2024; 194:105-117. [PMID: 39019395 DOI: 10.1016/j.yjmcc.2024.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 07/12/2024] [Accepted: 07/14/2024] [Indexed: 07/19/2024]
Abstract
A better understanding of the underlying pathomechanisms of diastolic dysfunction is crucial for the development of targeted therapeutic options with the aim to increase the patients' quality of life. In order to shed light on the processes involved, suitable models are required. Here, effects of endothelin-1 (ET-1) treatment on cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs) were investigated. While it is well established, that ET-1 treatment induces hypertrophy in cardiomyocytes, resulting changes in cell mechanics and contractile behavior with focus on relaxation have not been examined before. Cardiomyocytes were treated with 10 nM of ET-1 for 24 h and 48 h, respectively. Hypertrophy was confirmed by real-time deformability cytometry (RT-DC) which was also used to assess the mechanical properties of cardiomyocytes. For investigation of the contractile behavior, 24 h phase contrast video microscopy was applied. To get a deeper insight into changes on the molecular biological level, gene expression analysis was performed using the NanoString nCounter® cardiovascular disease panel. Besides an increased cell size, ET-1 treated cardiomyocytes are stiffer and show an impaired relaxation. Gene expression patterns in ET-1 treated hiPSC derived cardiomyocytes showed that pathways associated with cardiovascular diseases, cardiac hypertrophy and extracellular matrix were upregulated while those associated with fatty acid metabolism were downregulated. We conclude that alterations in cardiomyocytes after ET-1 treatment go far beyond hypertrophy and represent a useful model for diastolic dysfunction.
Collapse
Affiliation(s)
- Caterina Redwanz
- Department for Internal Medicine B, Cardiology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany; German Centre for Cardiovascular Research (DZHK), partner site Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.
| | - Ricardo H Pires
- Institute of Physics, University of Greifswald, Felix-Hausdorff-Straße 6, 17489 Greifswald, Germany; Centre for Innovation Competence - Humoral Immune Response in Cardiovascular Diseases, University Medicine Greifswald, Friedrich-Ludwig-Jahn-Straße 15a, 17489 Greifswald, Germany
| | - Doreen Biedenweg
- Institute of Physics, University of Greifswald, Felix-Hausdorff-Straße 6, 17489 Greifswald, Germany; Centre for Innovation Competence - Humoral Immune Response in Cardiovascular Diseases, University Medicine Greifswald, Friedrich-Ludwig-Jahn-Straße 15a, 17489 Greifswald, Germany.
| | - Stefan Groß
- Department for Internal Medicine B, Cardiology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany; German Centre for Cardiovascular Research (DZHK), partner site Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.
| | - Oliver Otto
- German Centre for Cardiovascular Research (DZHK), partner site Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany; Institute of Physics, University of Greifswald, Felix-Hausdorff-Straße 6, 17489 Greifswald, Germany; Centre for Innovation Competence - Humoral Immune Response in Cardiovascular Diseases, University Medicine Greifswald, Friedrich-Ludwig-Jahn-Straße 15a, 17489 Greifswald, Germany.
| | - Stephanie Könemann
- Department for Internal Medicine B, Cardiology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany; German Centre for Cardiovascular Research (DZHK), partner site Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.
| |
Collapse
|
4
|
Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, Fischer Y, Hocher B. Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibitor SLV338 Prevents Hypertensive Cardiac Remodeling in a Blood Pressure–Independent Manner. Hypertension 2011; 57:755-63. [DOI: 10.1161/hypertensionaha.110.163972] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Hypertensive heart disease is a major contributor to cardiovascular mortality. Endothelin is a potent vasoconstrictive and profibrotic mediator produced by the endothelin-converting enzyme (ECE), whereas natriuretic peptides, degraded by the neutral endopeptidase (NEP), have diuretic, vasodilatory, and antifibrotic properties. Thus, combined ECE/NEP inhibition may halt hypertensive cardiac remodeling. This study examined effects of SLV338, a novel ECE/NEP inhibitor, on cardiac protection in experimental renovascular hypertension (2-kidney, 1-clip [2K1C]). Male rats were allocated to 5 groups: sham-operated rats, untreated animals with 2K1C, 2K1C animals treated with oral SLV338 (30 and 100 mg/kg per day), and 2K1C animals treated with oral losartan (20 mg/kg per day). Treatment duration was 12 weeks. Blood pressure was assessed every 4 weeks. At study end, hearts were taken for histology/computer-aided histomorphometry/immunohistochemistry. Pharmacological properties of SLV338 are described. SLV338 is a dual ECE/NEP inhibitor, as demonstrated both in vitro and in vivo. In the 2K1C study, losartan lowered blood pressure by ≤46 mm Hg, whereas both dosages of SLV338 had no effect. However, SLV338 (both dosages) completely normalized cardiac interstitial fibrosis, perivascular fibrosis, myocyte diameter, and media:lumen ratio of cardiac arteries, as did losartan. Cardiac transforming growth factor-β1 expression was significantly enhanced in untreated 2K1C rats versus controls, whereas treatment with SLV338 and losartan prevented this effect. Taken together, dual ECE/NEP inhibitor SLV338 prevents cardiac remodeling to the same extent as losartan, but in a blood pressure–independent manner, in a rat model of renovascular hypertension. This effect is at least partially mediated via suppression of cardiac transforming growth factor-β1 expression.
Collapse
Affiliation(s)
- Philipp Kalk
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Yuliya Sharkovska
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Elena Kashina
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Karoline von Websky
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Katharina Relle
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Thiemo Pfab
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Markus Alter
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Philippe Guillaume
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Daniel Provost
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Katrin Hoffmann
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Yvan Fischer
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| | - Berthold Hocher
- From the Department of Nephrology (P.K., T.P., M.A.), Charité, Campus Benjamin Franklin, Berlin, Germany; Center for Cardiovascular Research/Institute of Pharmacology (P.K., Y.S., E.K., K.v.W., K.R., T.P., M.A., B.H.), Charité, Campus Mitte, Berlin, Germany; Institute for Nutritional Science (Y.S., K.v.W., K.R., B.H.), University of Potsdam, Potsdam, Germany; Porsolt and Partners Pharmacology (P.G., D.P.), Le Genest-Saint-Isle, France; Abbott Products GmbH (K.H., Y.F.), Hannover, Germany; and
| |
Collapse
|